SHIFT AI Newsroom · UK
Semaglutide (Wegovy, Ozempic and Rybelsus): Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus)
The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus). This update is relevant to UK patients and healthcare professionals, as Semaglutide is licensed and available in the UK for the treatment of certain conditions.
What this means in the UK
This update is relevant to UK patients and healthcare professionals, as Semaglutide is licensed and available in the UK for the treatment of certain conditions
Known facts
- The MHRA has issued a drug safety update regarding the risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) associated with Semaglutide (Wegovy, Ozempic and Rybelsus)